Medicine & TechnologyThis work does not only offer an affordable treatment strategy for chronic hepatitis B patients in developing countries but also reduces the required dose of RNAi drugs to minimize the potential side effects of RNAi therapy and allow the administration for a relatively long period or in conjunction with other antiviral drugs